# Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma

> **NCT00053326** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (estimated)

## Conditions studied

- Recurrent Neuroblastoma

## Interventions

- **DRUG:** fenretinide
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00053326
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2013-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053326, "Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00053326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*